{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:40:06Z","timestamp":1756737606835,"version":"3.44.0"},"reference-count":18,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0019","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T06:55:22Z","timestamp":1746514522000},"source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab, Venetoclax, and Azacitidine in Combination with HAA Regimen as Consolidation Chemotherapy for T-cell Acute Lymphoblastic Leukemia with High CD38 Expression"],"prefix":"10.4274","author":[{"given":"Lin-sen","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San-bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","article-title":"Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series","volume":"62","author":"Wan","year":"2021","unstructured":"1. Wan CL, Zou JY, Qiao M, Yin J, Shen XD, Qiu QC, Liu SB, Xue SL. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62:3300-3303.","journal-title":"Leuk Lymphoma"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1080\/10428194.2024.2390572","article-title":"Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature","volume":"65","author":"Jeanselme","year":"2024","unstructured":"2. Jeanselme P, Tavitian S, Lapierre L, Vergez F, Rigolot L, Huynh A, Bertoli S, Delabesse E, Huguet F. Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature. Leuk Lymphoma. 2024;65:2025-2030.","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","article-title":"Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen","volume":"99","author":"Zhang","year":"2020","unstructured":"3. Zhang X, Li J, Jin J, Yu W. Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol. 2020;99:395-397.","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12185-023-03623-w","article-title":"Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review","volume":"118","author":"Zhao","year":"2023","unstructured":"4. Zhao Y, Jiang S, Tang Y, Zhao L. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023;118:483-488.","journal-title":"Int J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","unstructured":"5. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:212-218.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","unstructured":"6. Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14:599-608.","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00277-013-1758-5","article-title":"Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory\/relapsed acute myeloid leukemia: a single-center experience","volume":"92","author":"Yu","year":"2013","unstructured":"7. Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory\/relapsed acute myeloid leukemia: a single-center experience. Ann Hematol. 2013;92:1091-1100.","journal-title":"Ann Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00277-023-05400-5","article-title":"Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia","volume":"102","author":"Duan","year":"2023","unstructured":"8. Duan W, Yang S, Zhao T, Hu L, Qin Y, Jia J, Wang J, Lu S, Jiang H, Zhang X, Xu L, Wang Y, Lai Y, Shi H, Huang X, Jiang Q. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia. Ann Hematol. 2023;102:2695-2705.","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","unstructured":"9. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995-999.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3324\/haematol.2023.283814","article-title":"Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia","volume":"109","author":"Koslowski","year":"2024","unstructured":"10. Koslowski S, Glauben R, Habringer S, Burmeister T, Keller U, Br\u00fcggemann M, G\u00f6kbuget N, Schwartz S. Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia. Haematologica. 2024;109:661-665.","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Liao C, Wang Y, Huang Y, Duan Y, Liang Y, Chen J, Jiang J, Shang K, Zhou C, Gu Y, Liu N, Zeng X, Gao X, Tang Y, Sun J. CD38-specific CAR Integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells. Adv Sci (Weinh). 2023;10:e2207394.","DOI":"10.1002\/advs.202207394"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","unstructured":"12. Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill S. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7:4418-4430.","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1228481","DOI":"10.3389\/fonc.2023.1228481","article-title":"The role of daratumumab in relapsed\/refractory CD38 positive acute leukemias-case report on three cases with a literature review","volume":"13","author":"Prejzner","year":"2023","unstructured":"13. Prejzner W, Pieko\u015b O, Be\u0142dzi\u0144ska K, Sadowska-Klasa A, Zarzycka E, Bieniaszewska M, Lewandowski K, Zaucha JM. The role of daratumumab in relapsed\/refractory CD38 positive acute leukemias-case report on three cases with a literature review. Front Oncol. 2023;13:1228481.","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1007\/s00277-024-05892-9","article-title":"The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience","volume":"103","author":"Dai","year":"2024","unstructured":"14. Dai Y, Luo L, Wei Z, Cheng P, Luo J, Li J. The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience. Ann Hematol. 2024;103:4057-4063.","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","article-title":"Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: single-arm, open-label, phase I study","volume":"103","author":"Shi","year":"2024","unstructured":"15. Shi H, Yang F, Cao M, Xu T, Zheng P, Guo Y, Su G, Feng S, Li R, Liu R, Liu H, Ma L, Ke X, Hu K. Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: single-arm, open-label, phase I study. Ann Hematol. 2024;103:2993-3004.","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood.2023023400","article-title":"Homoharringtonine inhibits the NOTCH\/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia","volume":"144","author":"Suo","year":"2024","unstructured":"16. Suo S, Zhao D, Li F, Zhang Y, Rodriguez-Rodriguez S, Nguyen LXT, Ghoda L, Carlesso N, Marcucci G, Zhang B, Jin J. Homoharringtonine inhibits the NOTCH\/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia. Blood. 2024;144:1343-1347.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","article-title":"Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia","volume":"150","author":"Yin","year":"2024","unstructured":"17. Yin Z, Yao Z, Chen D, Zhang Y, Weng G, Du X, Lin D, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Zhao W, Xuan L, Jiang X, Shi P, Liu Q, Ping B, Yu G. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. J Cancer Res Clin Oncol. 2024;150:336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","unstructured":"18. Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol. 2023;16:42.","journal-title":"J Hematol Oncol"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:03:18Z","timestamp":1756735398000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-82150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":18,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0019","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}